{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-033155","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.126943+00:00","generated_at":"2026-06-04T12:49:20.066652+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cerus INTERCEPT RBC Phase 3 trial meets primary non-inferiority endpoint","bullets":["AKI incidence 29.3% (INTERCEPT RBC) vs 28.0% (conventional); non-inferiority margin 14% (p=0.001).","Related TEAEs within 28 days: 2.5% vs 0.6% (p=0.130); no adverse health effects from RBC antibodies.","Modular PMA submission to FDA planned H2 2025; final module expected H2 2026 after RedeS trial.","ReCePI trial enrolled 581 patients at 18 U.S. sites; funded in part by BARDA contract."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-033155","json":"https://secwatch.observer/filing/0000950170-24-033155.json","markdown":"https://secwatch.observer/filing/0000950170-24-033155.md","text":"https://secwatch.observer/filing/0000950170-24-033155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024033155/0000950170-24-033155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000095017024033155/cers-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T12:49:20.066652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}